Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc. (ARCT): 23 pipeline candidates · 1 upcoming catalyst · ~33 mo cash runway · 6 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
33.1 months
D/E 0.28 · 0% dilution
Lead: Phase 3
23 candidates
1 upcoming, next in ~75d
N/A
A transparent, data-derived signal for Arcturus Therapeutics Holdings Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$209.2M
Cash
$213.4M
Quarterly Burn
$19.4M
Runway
33.1 mo
Revenue
$2.1M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (23 candidates)
| Drug | Phase |
|---|---|
| ARCT-021 | Phase 2 |
| ARCT-021 single dose priming | Phase 2 |
| ARCT-021 two higher dose priming | Phase 2 |
| ARCT-021 two lower dose priming | Phase 2 |
| ARCT-032 | Phase 2 |
| ARCT-154 | Phase 2 |
| ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine | Phase 2 |
| ARCT-165 | Phase 1 |
| ARCT-2301 (bivalent KOSTAIVE) | Phase 3 |
| ARCT-2303 (Monovalent XBB1.5) | Phase 3 |
Showing 10 of 23 candidates. Sign up for full pipeline.
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
125
Total value held
$177.6M
| Holder | Shares | Value |
|---|---|---|
| federated hermes, inc. | 3,303,640 | $25.5M |
| ark investment management llc | 2,769,518 | $21.4M |
| blackrock, inc. | 2,613,281 | $20.2M |
| amova asset management americas, inc. | 2,288,935 | $17.6M |
| vanguard capital management llc | 2,214,040 | $17.1M |
| two sigma investments, lp | 1,081,784 | $8.4M |
| vanguard portfolio management llc | 977,922 | $7.5M |
| geode capital management, llc | 660,928 | $5.1M |
| state street corp | 543,863 | $4.2M |
| millennium management llc | 478,557 | $3.7M |
Showing top 10 of 125 institutional holders of Arcturus Therapeutics Holdings Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Arcturus Therapeutics Holdings Inc.'s pipeline?
Arcturus Therapeutics Holdings Inc. (ARCT) has 23 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Arcturus Therapeutics Holdings Inc.'s lead drug candidate?
Arcturus Therapeutics Holdings Inc.'s most advanced tracked candidate is ARCT-021 (Phase 2) for COVID-19.
What is Arcturus Therapeutics Holdings Inc.'s next catalyst?
Arcturus Therapeutics Holdings Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Multicenter, Double-Blind, Randomized, Controlled Trial of the Safety and Immunogenicity " — expected September 1, 2026.
What is Arcturus Therapeutics Holdings Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Arcturus Therapeutics Holdings Inc. has approximately 33.1 months of cash runway.
What is Arcturus Therapeutics Holdings Inc.'s market capitalization?
Arcturus Therapeutics Holdings Inc.'s market capitalization is approximately $209.2M.
Get the full picture on Arcturus Therapeutics Holdings Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.